Mindset Pharma (MSSTF) has been made aware that Reunion Neuroscience (REUN) has filed a lawsuit against Mindset in the United States District Court for the District of New Jersey asserting, among others, inventorship and co-ownership of one of Mindset’s patents, inequitable conduct, and breach of contract. Mindset disagrees with and denies the allegations set forth from Reunion. The Company plans to vigorously defend itself against this lawsuit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REUN:
- Reunion Neuroscience Files Lawsuit Against Mindset Pharma
- Reunion Neuroscience files lawsuit against Mindset Pharma
- Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
- Reunion Neuroscience reports Q3 EPS (C$1.07) vs. (C$0.51) last year
- Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results